Smartphones for Opiate Addiction Recovery

Recruiting now · Phase 3

Conditions studied: Opioid-use Disorder

In brief

Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the numerical probability that a patient will reuse illicit opiates within the next 7-10 days.

Key facts

Study ID

NCT05033028

Run by

NYU Langone Health

People needed

225

Starts

2021-11-01

Expected to finish

2027-12-01

Last updated by the study team

2026-06-23

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients:
• Meet DSM-5 criteria for opioid-use disorder (heroin and/or prescription opioids);
• Have entered, or expressed a clear intention to enter, an OUD treatment program that prescribes either methadone or buprenorphine
• Any gender;
• 18 years of age and older;
• Have used opioids other than as specifically prescribed within thirty days prior to consent;
• In good-enough general health;
• Capacity to provide written informed consent as assessed by our Subject Comprehension Assessment Tool(subjects lacking the ability to consent will not be enrolled) ;
• Able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.
• Study-Physician Participants.
• Licensed MD employed by the respective site, or at a clinical partner of the respective site, where they will act as participants and be part of the treatment team
• Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;
• Able to speak, read, and write English fluently and to provide informed consent in English
• Clinician Participants.
• Licensed MSW, NP, or MD; who are not part of any treatment team within the study and may be employees of their respective sites or other treatment facilities.
• Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;
• Able to speak, read, and write English fluently and to provide informed consent in English

You may not qualify if…

• Patients:
• Serious medical, psychiatric or non-opioid substance use disorder that, in the opinion of a study physician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include: (a) Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
• Severe, untreated or inadequately treated mental disorder (e.g., active psychosis, uncontrolled manic-depressive illness) as assessed by history and/or clinical interview;
• Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use likely to require a complicated medical detoxification (routine alcohol and sedative detoxifications may be included);
• Suicidal or homicidal ideation that requires immediate attention;
• Presence of pain of sufficient severity as to require ongoing pain management with opioids;
• Pending legal action or other reasons that might prevent an individual from completing the study.
• Pregnancy as assessed by urine pregnancy testing
• Breastfeeding of infants, as assessed by self-report.
• Prisoners, as defined by OHRP, are excluded from participation in the study.
• Individuals receiving residential court-ordered substance abuse treatment.
• Study-Physician Participants.
• none
• Clinician Participants.
• none

Where it is running

• NYU Langone — New York, New York, United States (enrolling)
• Rutgers University — Piscataway, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.